Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;11(4):814-821.
doi: 10.1177/1932296817694913. Epub 2017 Mar 1.

A New Optimized Percutaneous Access System for CIPII

Rosa Garcia-Verdugo  1 , Michael Erbach  1 , Oliver Schnell  1   2
Affiliations

A New Optimized Percutaneous Access System for CIPII

Rosa Garcia-Verdugo et al. J Diabetes Sci Technol. 2017 Jul.

Abstract

In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.

Keywords: CIPII; hypoglycemia; subcutaneous insulin resistance; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Intraperitoneal insulin administration.
Figure 2.
Figure 2.
System components.
See this image and copyright information in PMC

Comment in

References

    1. Renard E. Continuous intraperitoneal insulin infusion from implantable pumps. In: Bruttomesso GG, ed. Technological Advances in the Treatment of Type 1 Diabetes. Basel, Switzerland: Karger; 2015:190-209.
    1. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med. 1986;315(3):147-153. - PubMed
    1. Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum. Adv Endocrinol Metab. 1995;6:193-232. - PubMed
    1. Soudan B, Girardot C, Fermon C, et al. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab. 29(5):539-546. - PubMed
    1. Ahmed Z, Prasad I, Rahman H, et al. A male with extreme subcutaneous insulin resistance: a case report. Rom J Diabetes Nutr Metab Dis. 2016;23(2):209-213. - PMC - PubMed

Publication types

MeSH terms